Strekin

Recent Finacing

Series A

Recent Raise

$2.9M

Strekin AG is a Basel clinical-stage biopharmaceutical developing STR001, a PPARγ agonist reducing cochlear oxidative stress and inflammation, currently in pivotal trials for sudden sensorineural hearing loss.

Founded 2014

Basel-Stadt, Switzerland

11-50

Private

strekin.com

Highlights

Focus Areas

Biotechnology

Health Care

Pharmaceutical

Financials

$13.2M

Total Raised

2

Funding rounds

Team

Upgrade to view the team

See the team members at Strekin.